Jacques Banchereau
Direktor/Vorstandsmitglied bei Ascend Biopharmaceuticals Ltd.
Profil
Jacques Banchereau is currently a Non-Executive Director at Ascend Biopharmaceuticals Ltd.
and a Director-Immunological Science Division at Jax Genomic Medicine.
He was previously the SVP, Head-Inflammation & Virology Discovery at Roche Ltd.
from 2010.
Prior to that, he worked as a Provisional Director at Neovacs SA.
Aktive Positionen von Jacques Banchereau
| Unternehmen | Position | Beginn |
|---|---|---|
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Corporate Officer/Principal | 06.10.2010 |
| Jax Genomic Medicine | Corporate Officer/Principal | - |
Ascend Biopharmaceuticals Ltd.
 Ascend Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Ascend Biopharmaceuticals Ltd. is a cancer immunotherapy company that develops medicines to treat primary, recurrent, and metastatic cancers. It offers pipeline strategy that focuses on a number of oncology and dermato-oncology settings. The company was founded by Clement Leong on September 10, 2003 and is headquartered in Melbourne, Australia. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jacques Banchereau
| Unternehmen | Position | Ende |
|---|---|---|
| NEOVACS | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NEOVACS | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Roche Ltd.
Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Finance |
| Jax Genomic Medicine | |
Ascend Biopharmaceuticals Ltd.
Ascend Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Ascend Biopharmaceuticals Ltd. is a cancer immunotherapy company that develops medicines to treat primary, recurrent, and metastatic cancers. It offers pipeline strategy that focuses on a number of oncology and dermato-oncology settings. The company was founded by Clement Leong on September 10, 2003 and is headquartered in Melbourne, Australia. | Health Technology |
